We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Vertex Pharmaceuticals saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The company ...

This period of growth follows what Pirnat called “20 straight months of down.” Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) and Boston Scientific Corp. were among the large, local companies to ...